ERBB2 and breast cancer: Previous clinical trials have found that the addition of trastuzumab and pertuzumab Carsten et al. to adjuvant chemotherapy does not result in a prognostic benefit for patients with HER2-low BC (Fehrenbacher et al., 2020; Schneeweiss et al., 2018).